Holland & Hart represented BayMedica Inc., a private company specializing in the manufacturing and commercialization of rare cannabinoids for the health and wellness sector, in its acquisition by InMed Pharmaceuticals Inc., a leader in the manufacturing and clinical development of rare cannabinoids.
The transaction combines the organizations’ capabilities and resources to accelerate BayMedica’s commercial initiatives and expedite the launch of several new cannabinoids products in the consumer health and wellness sector. The combined technologies in rare cannabinoid manufacturing, in three distinct and complementary manufacturing approaches, establishes the company as a leader in the field.
The Holland & Hart transactional team was led by corporate partner David Garcia, with assistance from Todd Criger, Robert Denzer, Peter Perla, Trent Timmons, John Wilson, John Ludlum, Mark Wiletsky, and Lori Argall.
For more information, please view InMed’s press release.
Holland & Hart’s Corporate attorneys have extensive experience advising clients from start-ups to public companies, at all stages of development, in a diverse range of industries, including healthcare, construction and building materials, energy and resources, technology, finance, gaming, outdoor recreation, animal health, aerospace, and food, beverage, and consumer products industries.